Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 04-Mar-24 4:26 PM View:  | Smith Thomas B EVP and Chief Medical Officer | Collegium Pharmaceutical, Inc (COLL) | 29-Feb-24 | Private Sale | 995 | $36.76 | $36,580.20 | (2%) 64.4K to 63.41K | |
| 28-Feb-24 10:00 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 26-Feb-24 | Private Sale (Planned) | 10,000 | $36.43 | $364,270.00 | (7%) 148.92K to 138.92K | |
| 14-Feb-24 4:14 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Grant | 76,647 | -- | -- | 64% 119.52K to 196.16K | |
| 14-Feb-24 4:13 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Grant | 298,734 | -- | -- | 109% 275.0K to 573.73K | |
| 14-Feb-24 4:14 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Grant | 67,286 | -- | -- | 60% 111.32K to 178.61K | |
| 14-Feb-24 4:14 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Payment of Exercise | 31,756 | $33.70 | $1,070,180.00 | (16%) 196.16K to 164.41K | |
| 14-Feb-24 4:15 PM View: | Tupper Colleen EVP & Chief Financial Officer | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Grant | 71,456 | -- | -- | 68% 105.42K to 176.88K | |
| 14-Feb-24 4:14 PM View: | Smith Thomas B EVP and Chief Medical Officer | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Grant | 35,423 | -- | -- | 110% 32.18K to 67.6K | |
| 14-Feb-24 4:13 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Payment of Exercise | 128,867 | $33.70 | $4,342,820.00 | (22%) 573.73K to 444.87K | |
| 14-Feb-24 4:14 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Payment of Exercise | 29,690 | $33.70 | $1,000,550.00 | (17%) 178.61K to 148.92K | |
| 14-Feb-24 4:15 PM View: | Tupper Colleen EVP & Chief Financial Officer | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Payment of Exercise | 26,321 | $33.70 | $887,018.00 | (15%) 176.88K to 150.56K | |
| 14-Feb-24 4:14 PM View: | Smith Thomas B EVP and Chief Medical Officer | Collegium Pharmaceutical, Inc (COLL) | 12-Feb-24 | Payment of Exercise | 3,199 | $33.70 | $107,806.00 | (5%) 67.6K to 64.4K | |
| 18-Jan-24 4:19 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 16-Jan-24 | Private Sale (Planned) | 23,560 | $32.28 | $760,519.00 | (17%) 134.88K to 111.32K | |
| 22-Dec-23 4:36 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 21-Dec-23 | Planned Option Sale | 4,357 | $30.38 | $132,377.00 | (2%) 279.36K to 275.0K | |
| 22-Dec-23 4:36 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 21-Dec-23 | Option Exercise | 4,357 | $21.34 | $92,978.40 | 2% 275.0K to 279.36K | |
| 20-Dec-23 5:51 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 20-Dec-23 | Option Exercise | 26,454 | $21.34 | $564,528.00 | 10% 275.0K to 301.45K | |
| 20-Dec-23 5:51 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 20-Dec-23 | Planned Option Sale | 26,454 | $30.40 | $804,210.00 | (9%) 301.45K to 275.0K | |
| 20-Dec-23 5:51 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 19-Dec-23 | Option Exercise | 14,516 | $21.34 | $309,771.00 | 5% 275.0K to 289.52K | |
| 20-Dec-23 5:51 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 19-Dec-23 | Planned Option Sale | 14,516 | $30.03 | $435,942.00 | (5%) 289.52K to 275.0K | |
| 20-Dec-23 5:51 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 18-Dec-23 | Planned Option Sale | 27,798 | $30.04 | $834,935.00 | (9%) 302.8K to 275.0K | |
| 20-Dec-23 5:51 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 18-Dec-23 | Option Exercise | 27,798 | $21.34 | $593,209.00 | 10% 275.0K to 302.8K | |
| 29-Nov-23 4:32 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 27-Nov-23 | Option Exercise | 25,600 | $15.90 | $407,040.00 | 21% 119.52K to 145.12K | |
| 29-Nov-23 4:32 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 27-Nov-23 | Planned Option Sale | 25,600 | $25.78 | $660,014.00 | (18%) 145.12K to 119.52K | |
| 28-Jun-23 4:08 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 26-Jun-23 | Private Sale (Planned) | 17,984 | $21.72 | $390,633.00 | (13%) 137.5K to 119.52K | |
| 02-Jun-23 7:08 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 02-Jun-23 | Sale (Planned) | 31,272 | $21.60 | $675,424.00 | (10%) 306.27K to 275.0K | |
| 02-Jun-23 7:08 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 01-Jun-23 | Private Sale (Planned) | 31,272 | $22.09 | $690,758.00 | (9%) 337.54K to 306.27K | |
| 01-Jun-23 4:15 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 31-May-23 | Sale (Planned) | 31,272 | $21.87 | $683,797.00 | (8%) 368.82K to 337.54K | |
| 01-Jun-23 4:15 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 30-May-23 | Private Sale (Planned) | 31,271 | $21.90 | $684,907.00 | (8%) 400.09K to 368.82K | |
| 19-May-23 4:40 PM View: | Balice-Gordon Rita J. Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 34% 29.0K to 38.8K | |
| 19-May-23 4:39 PM View: | Freund John Gordon Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 12% 78.4K to 88.19K | |
| 19-May-23 4:38 PM View: | Melincoff Gwen A Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 28% 34.98K to 44.77K | |
| 19-May-23 4:37 PM View: | Bohlin Garen G Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 28% 34.98K to 44.77K | |
| 19-May-23 4:39 PM View: | Fallon John A. Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 26% 37.36K to 47.15K | |
| 19-May-23 4:40 PM View: | McFarlane Neil F. Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 31% 31.88K to 41.67K | |
| 19-May-23 4:38 PM View: | Santini Gino Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 17% 58.17K to 67.96K | |
| 19-May-23 4:40 PM View: | Heffernan Michael Thomas Director | Collegium Pharmaceutical, Inc (COLL) | 18-May-23 | Grant | 9,792 | -- | -- | 35% 28.02K to 37.81K | |
| 17-Mar-23 4:11 PM View: | Tupper Colleen EVP & Chief Financial Officer | Collegium Pharmaceutical, Inc (COLL) | 15-Mar-23 | Private Sale (Planned) | 31,640 | $23.77 | $752,165.00 | (23%) 137.06K to 105.42K | |
| 03-Mar-23 4:08 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 01-Mar-23 | Private Sale (Planned) | 13,324 | $26.70 | $355,751.00 | (9%) 148.21K to 134.88K | |
| 14-Feb-23 5:16 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 13-Feb-23 | Planned Option Sale | 11,250 | $26.88 | $302,400.00 | (3%) 411.34K to 400.09K | |
| 14-Feb-23 5:18 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 13-Feb-23 | Sale (Planned) | 21,811 | $26.88 | $586,280.00 | (14%) 159.31K to 137.5K | |
| 14-Feb-23 5:16 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 13-Feb-23 | Option Exercise | 11,250 | $15.90 | $178,875.00 | 3% 400.09K to 411.34K | |
| 14-Feb-23 5:15 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Payment of Exercise | 21,326 | $26.75 | $570,470.00 | (13%) 169.53K to 148.21K | |
| 14-Feb-23 5:16 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Payment of Exercise | 103,857 | $26.75 | $2,778,170.00 | (21%) 503.94K to 400.09K | |
| 14-Feb-23 5:17 PM View: | Tupper Colleen EVP & Chief Financial Officer | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Grant | 57,610 | -- | -- | 64% 90.3K to 147.91K | |
| 14-Feb-23 5:19 PM View: | Smith Thomas B EVP and Chief Medical Officer | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Grant | 31,185 | -- | -- | 100% 0 to 31.18K | |
| 14-Feb-23 5:18 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Grant | 73,864 | -- | -- | 67% 109.5K to 183.36K | |
| 14-Feb-23 5:15 PM View: | Dreyer Scott EVP & Chief Commercial Officer | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Grant | 66,734 | -- | -- | 65% 102.8K to 169.53K | |
| 14-Feb-23 5:16 PM View: | Ciaffoni Joseph President and CEO Director | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Grant | 255,194 | -- | -- | 103% 248.75K to 503.94K | |
| 14-Feb-23 5:17 PM View: | Tupper Colleen EVP & Chief Financial Officer | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Payment of Exercise | 10,854 | $26.75 | $290,344.00 | (7%) 147.91K to 137.06K | |
| 14-Feb-23 5:18 PM View: | Kuhlmann Shirley R. EVP and General Counsel | Collegium Pharmaceutical, Inc (COLL) | 10-Feb-23 | Payment of Exercise | 24,046 | $26.75 | $643,230.00 | (13%) 183.36K to 159.31K |
